Keep the Conversation Focused on Preserving Sight

A patient may reasonably hear that THC lowers eye pressure and ask whether cannabis can replace eye drops. The answer supported by this review is no: it does not establish sustained control or prevention of glaucoma-related vision loss. A temporary improvement in one measurement cannot show that the optic nerve remains protected between measurements.

The practical conversation should be nonjudgmental. Patients should disclose cannabis use, including route and timing, while continuing prescribed treatment unless their eye-care clinician changes it. That information can help contextualize pressure readings and review possible systemic effects. Glaucoma management should remain anchored to individualized target pressure, disease severity, and scheduled monitoring. Open and transparent discussions with healthcare providers help clarify realistic treatment timelines, administration methods, and appropriate product selection. Establishing transparent safety protocols, certified testing benchmarks, and monitored patient responses remains the foundation of responsible cannabinoid medicine.

Route-Specific Results Do Not Supply a Cannabis Dose

Intravenous THC produced the largest pooled peak reduction, 33.27% (95% CI, 20.36% to 46.17%). That is a finding about a particular delivery route, not evidence that an oral edible or dispensary product will produce the same response.

The oral estimate was 10.65% (95% CI, -7.60% to 28.89%). The topical estimate was 9.36% (95% CI, -8.89% to 27.6%). Both intervals crossed zero, leaving benefit uncertain.

These subgroup estimates do not constitute a head-to-head route comparison. Differences between the underlying studies could contribute to the apparent separation.

The supplied abstract does not establish a therapeutic THC dose, dosing interval, or THC-to-CBD ratio. It also does not validate inhalation or homemade ocular preparations. Applying non-ophthalmic cannabis products to the eye is unsafe.

Pressure Reduction Must Be Weighed Against Systemic Effects

An eye-pressure effect is only one part of the safety equation. THC can cause intoxication, impaired attention, dizziness, and cardiovascular effects. These are established clinical considerations, not adverse-event rates demonstrated by the supplied abstract, which does not provide a pooled safety analysis.

For patients already vulnerable to falls, cognitive impairment, or medication-related dizziness, those effects may be especially relevant. Combining THC with other impairing substances can create additional practical risks.

Ocular perfusion also matters. A drug that changes systemic blood pressure may affect blood supply to the optic nerve, so a lower IOP reading alone does not establish a favorable overall physiologic effect. This review does not resolve that balance or demonstrate that repeated exposure is safe.

Legal Access Is Different From Evidence of Effectiveness

In jurisdictions where glaucoma qualifies for medical cannabis access, legal eligibility should not be mistaken for proof that THC is an effective replacement treatment. Access rules and clinical evidence answer different questions. This meta-analysis reports pressure responses, not a regulatory determination of safety and efficacy.

The largest estimated effect came from intravenous administration, which does not map onto ordinary retail cannabis access. Oral and topical findings were inconclusive, and the supplied abstract does not establish product consistency, long-term efficacy, or a standardized regimen. Public-facing claims should identify those distinctions rather than treating all cannabis products as interchangeable glaucoma therapies. Consistent administrative oversight and clear statutory definitions ensure that public health protections keep pace with evolving consumer formulations.

Pressure Biology Offers Plausibility, Not Proof of Protection

Intraocular pressure reflects the balance between aqueous humor production and drainage. Cannabinoid signaling offers biologically plausible pathways for influencing ocular physiology, but the review’s pooled pressure estimates do not identify which mechanism caused the observed changes.

Delivery route can alter exposure, onset, and the relationship between ocular and systemic effects. The intravenous signal may therefore inform pharmacologic research, but it does not demonstrate that oral or topical administration achieves an equivalent effect.

The optic nerve outcome remains separate. Reduced IOP can be clinically valuable in glaucoma, yet a peak response cannot establish durable benefit or a pressure-independent neuroprotective action. Neither mechanism nor vision protection should be inferred from these measurements alone. Investigating receptor affinities, pharmacokinetic pathways, and cellular interactions clarifies the biological mechanisms underlying observed clinical outcomes. Integrating longitudinal observations with objective symptom tracking provides patients and clinicians with clearer context for evaluating day-to-day therapeutic changes.

Small Samples and Peak Endpoints Restrict the Conclusions

With five studies and 99 participants, the review has limited capacity to deliver precise estimates across multiple administration routes. Wide intervals for oral, topical, and controlled results signal substantial uncertainty rather than a settled clinical answer.

Peak percentage reduction also depends on baseline IOP. The same percentage change can correspond to different absolute changes in millimeters of mercury, making baseline values important for judging clinical relevance.

Selecting the maximum observed response does not describe average control over the day. The abstract does not establish how consistently peaks were defined or whether measurement schedules were comparable.

Prospective registration and independent review improve transparency, but they cannot repair weaknesses in the underlying studies. Details about masking, comparator selection, missing data, and risk-of-bias judgments need confirmation in the full publication.

The Next Trials Need Sustained Control and Practical Delivery

A useful next study would test a standardized, clinically practical formulation against an appropriate comparator, with prespecified pressure measurements across the dosing interval. Absolute IOP changes, duration of effect, tolerability, and background glaucoma treatment should be reported clearly.

Longer studies would then need to examine whether treatment supports disease control without unacceptable ocular or systemic effects. Visual-field progression and structural optic nerve outcomes would be more informative for vision preservation than an isolated peak response. This review helps define the research gap, but it does not show that a cannabinoid formulation can already meet those requirements. Future prospective investigations with standardized formulations and long-term follow-up will provide critical clarity as clinical evidence matures.